# Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma

> **NCT05517330** · PHASE2 · COMPLETED · sponsor: **West China Hospital** · enrollment: 23 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** Tislelizumab
- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT05517330
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-19
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05517330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05517330, "Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05517330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*